vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and NUSCALE POWER Corp (SMR). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $8.2M, roughly 1.8× NUSCALE POWER Corp). On growth, NUSCALE POWER Corp posted the faster year-over-year revenue change (1635.2% vs -69.7%). Over the past eight quarters, NUSCALE POWER Corp's revenue compounded faster (22.4% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

NuScale Power Corporation is a publicly traded American company that designs and markets small modular reactors (SMRs). It is headquartered in Tigard, Oregon. The company's VOYGR power plant, which uses 50 MWe modules and scales to 12 modules, was the first SMR to be certified by the US Nuclear Regulatory Commission (NRC) (2022). The newer 77 MWe module designs, known as the VOYGR-4 and VOYGR-6, were submitted for NRC review on January 1, 2023, and approved May 29, 2025. NuScale is now seekin...

IRIX vs SMR — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.8× larger
IRIX
$14.7M
$8.2M
SMR
Growing faster (revenue YoY)
SMR
SMR
+1704.9% gap
SMR
1635.2%
-69.7%
IRIX
Faster 2-yr revenue CAGR
SMR
SMR
Annualised
SMR
22.4%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IRIX
IRIX
SMR
SMR
Revenue
$14.7M
$8.2M
Net Profit
$-273.3M
Gross Margin
37.2%
32.9%
Operating Margin
-6532.9%
Net Margin
-3316.2%
Revenue YoY
-69.7%
1635.2%
Net Profit YoY
-1465.5%
EPS (diluted)
$-1.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
SMR
SMR
Q4 25
$14.7M
Q3 25
$12.5M
$8.2M
Q2 25
$13.6M
$8.1M
Q1 25
$11.9M
$13.4M
Q4 24
$12.7M
$34.2M
Q3 24
$11.6M
Q2 24
$12.6M
Q1 24
$11.8M
Net Profit
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
$-1.6M
$-273.3M
Q2 25
$-994.0K
$-17.6M
Q1 25
$-1.7M
$-14.0M
Q4 24
$-834.0K
$-75.0M
Q3 24
$-1.9M
Q2 24
$-2.7M
Q1 24
$-3.5M
Gross Margin
IRIX
IRIX
SMR
SMR
Q4 25
37.2%
Q3 25
32.1%
32.9%
Q2 25
34.5%
22.1%
Q1 25
42.5%
52.4%
Q4 24
44.0%
91.1%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
-11.3%
-6532.9%
Q2 25
-6.9%
-534.9%
Q1 25
-1.7%
-264.1%
Q4 24
-3.9%
-34.6%
Q3 24
-16.1%
Q2 24
-20.9%
Q1 24
-28.0%
Net Margin
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
-12.6%
-3316.2%
Q2 25
-7.3%
-219.0%
Q1 25
-14.2%
-104.7%
Q4 24
-6.6%
-219.1%
Q3 24
-16.7%
Q2 24
-21.2%
Q1 24
-29.5%
EPS (diluted)
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
$-0.09
$-1.85
Q2 25
$-0.06
$-0.13
Q1 25
$-0.10
$-0.11
Q4 24
$-0.05
$-0.77
Q3 24
$-0.12
Q2 24
$-0.16
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
SMR
SMR
Cash + ST InvestmentsLiquidity on hand
$6.0M
$691.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$828.7M
Total Assets
$29.2M
$883.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
SMR
SMR
Q4 25
$6.0M
Q3 25
$5.6M
$691.8M
Q2 25
$6.8M
$420.7M
Q1 25
$7.2M
$521.4M
Q4 24
$2.4M
$441.6M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$5.4M
Total Debt
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
$4.7M
$828.7M
Q2 25
$6.1M
$692.9M
Q1 25
$852.0K
$704.0M
Q4 24
$2.1M
$618.7M
Q3 24
$2.6M
Q2 24
$4.2M
Q1 24
$6.5M
Total Assets
IRIX
IRIX
SMR
SMR
Q4 25
$29.2M
Q3 25
$28.4M
$883.1M
Q2 25
$31.6M
$606.5M
Q1 25
$34.2M
$618.1M
Q4 24
$29.1M
$544.7M
Q3 24
$30.2M
Q2 24
$31.2M
Q1 24
$34.1M
Debt / Equity
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
SMR
SMR
Operating Cash FlowLast quarter
$-199.8M
Free Cash FlowOCF − Capex
$-199.9M
FCF MarginFCF / Revenue
-2425.1%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
$-1.2M
$-199.8M
Q2 25
$-397.0K
$-33.3M
Q1 25
$-1.1M
$-22.8M
Q4 24
$-1.2M
$-26.4M
Q3 24
$-3.1M
Q2 24
$-1.3M
Q1 24
$-1.6M
Free Cash Flow
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
$-1.2M
$-199.9M
Q2 25
$-410.0K
Q1 25
$-1.2M
$-22.9M
Q4 24
$-1.2M
$-26.5M
Q3 24
$-3.1M
Q2 24
Q1 24
$-1.7M
FCF Margin
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
-9.4%
-2425.1%
Q2 25
-3.0%
Q1 25
-9.8%
-170.9%
Q4 24
-9.8%
-77.3%
Q3 24
-26.5%
Q2 24
Q1 24
-14.0%
Capex Intensity
IRIX
IRIX
SMR
SMR
Q4 25
Q3 25
0.1%
0.9%
Q2 25
0.1%
Q1 25
0.1%
0.5%
Q4 24
0.1%
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRIX
IRIX

Segment breakdown not available.

SMR
SMR

Power Plant And NPM Engineering Design And Licensing Services And Fees$8.0M97%
Other$208.0K3%

Related Comparisons